These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17328099)

  • 21. Administration of iduronate sulfatase by plasma exchange to patients with the Hunter syndrome: a clinical study.
    Brown FR; Hall CW; Neufeld EF; Munoz LL; Braine H; Andrzejewski S; Camargo EE; Mark SA; Richard JM; Moser HW
    Am J Med Genet; 1982 Nov; 13(3):309-18. PubMed ID: 6817638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parental experience of enzyme replacement therapy for Hunter syndrome.
    Buraczewska M; O'Leary D; Walsh O; Monavari A; Crushell E
    Ir Med J; 2013 Apr; 106(4):120-2. PubMed ID: 23691848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H; Chung JK; Mascelli MA; McCauley TG
    PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
    Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
    Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mucopolysaccharidosis type II (Hunter syndrome)].
    Sukegawa K; Tomatsu S; Kondo N; Orii T
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):435-8. PubMed ID: 9645102
    [No Abstract]   [Full Text] [Related]  

  • 26. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
    Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
    Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II].
    Orchel-Szastak K; Ptak K; Hrnciar K; Pilch B; Kania U; Bik-Multanowski M
    Pediatr Endocrinol Diabetes Metab; 2017; 23(2):111-116. PubMed ID: 29073295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
    Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xyrem approved for muscle problems in narcolepsy.
    FDA Consum; 2002; 36(5):7. PubMed ID: 12412541
    [No Abstract]   [Full Text] [Related]  

  • 31. Multidisciplinary management of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Escolar ML; Giugliani R; Guffon NH; Harmatz P; Kamin W; Kampmann C; Koseoglu ST; Link B; Martin RA; Molter DW; Muñoz Rojas MV; Ogilvie JW; Parini R; Ramaswami U; Scarpa M; Schwartz IV; Wood RE; Wraith E
    Pediatrics; 2009 Dec; 124(6):e1228-39. PubMed ID: 19901005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endovasc establishes orphan drug test.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):740-1. PubMed ID: 12458568
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hunter syndrome].
    Matsushita Y; Kuroiwa Y
    Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):462-3. PubMed ID: 11031993
    [No Abstract]   [Full Text] [Related]  

  • 34. Hints on preparing successful orphan drug designation requests.
    Buday PV
    Food Drug Law J; 1996; 51(1):75-84. PubMed ID: 11794354
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone marrow transplantation in Hunter syndrome: a preliminary report.
    Warkentin PI; Dixon MS; Schafer I; Strandjord SE; Coccia PF
    Birth Defects Orig Artic Ser; 1986; 22(1):31-9. PubMed ID: 3083885
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Despite surge in orphan drug designations, approvals still lag.
    Heger M
    Nat Med; 2011 Mar; 17(3):236. PubMed ID: 21383708
    [No Abstract]   [Full Text] [Related]  

  • 38. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 39. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 40. [Idursulfase desensitization in a child with Hunter syndrome (mucopolysaccharidosis II)].
    Bustamante LL; Garavaglia L; Garramone EI; Amartino H; Parisi CA
    Arch Argent Pediatr; 2021 Feb; 119(1):e41-e44. PubMed ID: 33458989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.